Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors

作者：Zhenyu Niu, Jianchun Wang, Jingru Ren, Qing Li, Jing Guo, Nan Zhang, Yiming Zheng, Hong-Jun Hao, Feng Gao, Haiqiang Jin · 发表于：Frontiers in Neurology · 年份：2025 · DOI：10.3389/fneur.2025.1715486 · 被引用次数：3 · 研究领域：Myasthenia Gravis and Thymoma、Adrenal Hormones and Disorders、Coagulation, Bradykinin, Polyphosphates, and Angioedema

Objective: This study aimed to identify predictors of suboptimal response to efgartigimod in patients with generalized myasthenia gravis (gMG). Methods: = 10). Responders were defined by a reduction of >2 points in MG-ADL or >3 points in QMG score after one cycle, whereas non-responders showed improvement below these thresholds and subsequently responded to eculizumab. Demographic, clinical, and serological features were compared using univariate and multivariate analyses. Results: Non-responders had higher baseline gross motor and respiratory sub-scores. Univariate analysis revealed that thymoma, non-thymoma tumors, thyroid disease, and other autoimmune diseases were more common in non-responders. Multivariate analysis indicated that combinations of these factors were associated with a high predicted probability of poor response (up to 97.9%). Interpretation: Comorbidities including thymoma, other tumors, thyroid disease, and additional autoimmune disorders may predict reduced response to efgartigimod in gMG patients. Systematic evaluation of these factors could help optimize treatment selection.